Back to Search
Start Over
Real-Life Effectiveness and Safety of Glecaprevir/Pibrentasvir for Korean Patients with Chronic Hepatitis C at a Single Institution
- Source :
- Gut and Liver. 15:440-450
- Publication Year :
- 2021
- Publisher :
- The Editorial Office of Gut and Liver, 2021.
-
Abstract
- Background/aims Glecaprevir/pibrentasvir (G/P) is a combination of direct-acting antiviral agents that is an approved treatment for chronic infections by all six hepatitis C virus (HCV) genotypes. However, there are limited data on the effect of G/P in Korean patients in actual real-world settings. We evaluated the real-life effectiveness and safety of G/P at a single institution in Korea. Methods This retrospective, observational, cohort study used sustained virologic response at 12 weeks after treatment completion (SVR12) as the primary effectiveness endpoint. Safety and tolerability were also determined. Results We examined 267 individuals who received G/P for chronic HCV infections. There were 148 females (55.4%), and the overall median age was 63.0 years (range, 25 to 87 years). Eighty-three patients (31.1%) had HCV genotype-1 and 182 (68.2%) had HCV-2. A total of 212 patients (79.4%) were HCV treatment-naive, 200 (74.9%) received the 8-week treatment, 13 (4.9%) had received prior treatment for hepatocellular carcinoma, 37 (13.7%) had chronic kidney disease stage 3 or higher, and 10 (3.7%) were receiving dialysis. Intention to treat (ITT) analysis indicated that 256 (95.9%) achieved SVR12. A modified ITT analysis indicated that SVR12 was 97.7% (256/262). Six patients failed therapy because of posttreatment relapse. SVR12 was significantly lower in those who received prior sofosbuvir treatment (p=0.002) and those with detectable HCV RNA at week 4 (p=0.027). Seventy patients (26.2%) experienced one or more adverse events, and most of them were mild. Conclusions These real-life data indicated that G/P treatment was highly effective and well tolerated, regardless of viral genotype or patient comorbidities.
- Subjects :
- Cyclopropanes
medicine.medical_specialty
Aminoisobutyric Acids
Pyrrolidines
Genotype
Proline
Sustained Virologic Response
Sofosbuvir
Lactams, Macrocyclic
Hepatitis C virus
Hepacivirus
medicine.disease_cause
Antiviral Agents
Cohort Studies
03 medical and health sciences
0302 clinical medicine
Leucine
Quinoxalines
Internal medicine
Republic of Korea
medicine
Humans
Retrospective Studies
Sulfonamides
Intention-to-treat analysis
Hepatology
business.industry
Gastroenterology
Hepatitis C
Glecaprevir
Hepatitis C, Chronic
Middle Aged
medicine.disease
Pibrentasvir
Treatment Outcome
Tolerability
030220 oncology & carcinogenesis
Benzimidazoles
Drug Therapy, Combination
Female
030211 gastroenterology & hepatology
Neoplasm Recurrence, Local
business
Kidney disease
medicine.drug
Subjects
Details
- ISSN :
- 20051212 and 19762283
- Volume :
- 15
- Database :
- OpenAIRE
- Journal :
- Gut and Liver
- Accession number :
- edsair.doi.dedup.....15cd1ff9e3ee0f878af3f6456f74ec2d